Updates on campus events, policies, construction and more.


Information for Our Community

Whether you are part of our community or are interested in joining us, we welcome you to Washington University School of Medicine.


Resources for drug discovery and development: Introducing VeritaScience, Feb. 13, 2024

January 24, 2024

Interested in drug discovery and development? Find out how VeritaScience could accelerate your research.

VeritaScience — a new private R&D collaboration between WashU and the health-care investment firm Deerfield Management — offers funding and expertise in drug discovery, development and commercialization to selected WashU investigators.

Accepted projects may benefit from

  • Funding for drug discovery and development
  • Collaboration with experienced drug developers
  • Continued ability to publish and present your work
  • Hands-on learning opportunities for graduate and postdoctoral trainees

Introducing VeritaScience:

Collaboration to accelerate translational drug discovery

Tuesday, February 13, 2024 | 10:30 am – 12 p.m.

EPNEC Auditorium
Washington University Medical Campus

In this session, you will learn about:

  • The partnership and its operating framework
  • Deerfield Management
  • Proposal submission process

Networking lunch to follow.


William Slattery

William Slattery is a partner on the Therapeutics team and joined the firm in 2000. Prior to Deerfield, Slattery was a senior health care analyst for 10 years at Amerindo Investment Advisors, where he oversaw biotechnology investments. He has held various positions in research including those at National Medical Enterprises, Johnson & Johnson, and HMSS. Slattery is the chairman of Gilda’s Club New York City, a non-profit organization supporting cancer patients and their families. He holds an undergraduate degree in biology and chemistry from State University of New York at Albany and completed coursework in immunology at the Graduate School-New Brunswick, Rutgers University.

Ivo Lorenz, PhD

Ivo Lorenz, PhD, is head of Biologics and Research Partnerships Lead, Deerfield Discovery and Development, and joined the firm in 2021. Prior to Deerfield, Lorenz was vice president, biologics at the Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI). Before the Tri-I TDI, he had group leader positions in R&D at Boehringer Ingelheim Pharmaceuticals and at the International AIDS Vaccine Initiative (IAVI). Lorenz holds a PhD in biochemistry and an M.Sc. and a B.Sc. in biochemistry and molecular biology from the Swiss Federal Institute of Technology in Zurich.

Eric Schiffhauer, PhD

Eric Schiffhauer, PhD, is a director, academic outreach, Deerfield Discovery and Development, and joined the firm in 2022. Prior to Deerfield, Schiffhauer spent three years at Northwestern University, most recently as a scientific collaboration director. Before Northwestern, he held positions at Adi Family Office and Johns Hopkins Technology Ventures. Schiffhauer holds a BS in biology from George Mason University and a PhD in biochemistry, cellular and molecular biology from Johns Hopkins University.

Schuyler Kennedy

Schuyler Kennedy is manager, research partnerships, Deerfield Discovery and Development, and joined the firm in 2020. Kennedy focuses on planning and executing strategic initiatives for Deerfield’s academic research collaborations. Prior to Deerfield, Kennedy spent two years as a care coordinator in the pediatric outpatient chemotherapy unit for Memorial Sloan Kettering Kids. She holds a BS in psychology from Fordham University.

Register to attend

Registration for this event has closed.